We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test May Help Detect Kidney Cancer Earlier

By LabMedica International staff writers
Posted on 26 Sep 2018
Renal cell carcinoma (RCC) has the potential for cure with surgery when diagnosed at an early stage. More...
Kidney injury molecule-1 (KIM-1) has been shown to be elevated in the plasma of RCC patients.

Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90% to 95% of cases.

Scientists from the Beth Israel Deaconess Medical Center (Boston, MA, USA) and their colleagues conducted a population-based prospective cohort study that included 190 patients who developed renal cell carcinoma within five years (cases) and 190 patients who remained healthy (controls). A risk model that included kidney injury molecule-1 significantly distinguished between cases and controls, compared with a risk model that included known risk factors of renal cell carcinoma, including age, sex, country, BMI and tobacco smoking status. Kidney injury molecule-1 (KIM-1) was measured in in pre-diagnostic plasma.

The team reported that they found that patients who eventually developed renal cell carcinoma had double the concentration of kidney injury molecule-1 in prediagnostic plasma (incidence rate ratio = 1.71 (95% CI, 1.44-2.03). They compared a risk model including known risk factors of RCC (age, sex, country, body mass index and tobacco smoking status), with a risk model additionally including KIM-1 substantially improved discrimination between cases and controls (area under the receiver operating characteristic curve of 0.8 compared to 0.7). High plasma KIM-1 concentrations were also associated with poorer survival.

The authors concluded that plasma KIM-1 concentrations could predict RCC incidence up to five years prior to diagnosis and were associated with poorer survival. Rupal Bhatt, MD, PhD, a medical oncologist and the senior author of the study, said, “Renal cell carcinoma has the potential for cure with surgery when diagnosed at an early stage. Kidney injury molecule-1 has been shown to be elevated in the plasma of renal cell carcinoma patients.” The study was published on September 6, 2018, in the journal Clinical Cancer Research.

Related Links:
Beth Israel Deaconess Medical Center


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.